Patients harboring rearrangements of the ROS1 gene are eligible for first-line therapy with Crizotinib, which represents the best available treatment option. Diagnostic criteria, based on break-apart fluorescence in situ hybridization, were mirrored from ALK by analogy and include tumors with 5' deletions. However, the probability of response to Crizotinib in patients with 5' deletion in ROS1 is unknown given the rarity of this condition.
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer / Capizzi E.; Dall'Olio F.G.; Gruppioni E.; Sperandi F.; Altimari A.; Giunchi F.; Fiorentino M.; Ardizzoni A.. - In: LUNG CANCER. - ISSN 0169-5002. - STAMPA. - 135:(2019), pp. 88-91. [10.1016/j.lungcan.2019.07.017]
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer
Capizzi E.;Dall'Olio F. G.;Fiorentino M.
;Ardizzoni A.
2019
Abstract
Patients harboring rearrangements of the ROS1 gene are eligible for first-line therapy with Crizotinib, which represents the best available treatment option. Diagnostic criteria, based on break-apart fluorescence in situ hybridization, were mirrored from ALK by analogy and include tumors with 5' deletions. However, the probability of response to Crizotinib in patients with 5' deletion in ROS1 is unknown given the rarity of this condition.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
